Ono Gislaine, Medina Pestana José Osmar, Aranha Camargo Luís Fernando
Division of Infectious Diseases, Department of Medicine, Universidade Federal de São Paulo (UNIFESP), Sao Paulo, Brazil.
Department of Medicine, Head of transplant division Hospital do Rim, Universidade Federal de São Paulo (UNIFESP), Sao Paulo, Brazil.
Transpl Infect Dis. 2019 Apr;21(2):e13035. doi: 10.1111/tid.13035. Epub 2018 Dec 28.
Late cytomegalovirus infections (LCMV) after the cessation of prophylaxis are well described. We aimed to assess clinical and epidemiological data on late-occurring cytomegalovirus (CMV) infections in the absence of CMV prophylaxis in a cohort of kidney transplant patients.
In a cohort of kidney transplant recipients not employing CMV-specific prophylaxis, patients with CMV infections occurring after 6 months of transplantation were compared to patients with CMV infections diagnosed within the first 6 months (early infections). The main objectives were to compare clinical outcomes and evaluate risk factors for late CMV infection.
A total of 556 patients were evaluated. Forty-three patients with LCMV infections were compared to 513 patients with early CMV infections. LCMV infections occurred after a median of 473 days of transplantation and had a more severe course, with a statistically significant higher rate of invasive disease and graft loss (60.5% vs 21.6% and 11.6% vs 3.1% respectively). Thirty-day mortality was twice as high for patients with LCMV, but did not reach statistical significance (9.3% vs 4.3%). By multivariate analysis, employment of antilymphocyte therapy early after transplantation and tacrolimus as initial immunosuppressive therapy were significantly protective for the occurrence of LCMV infections.
Late CMV infections in the absence of specific prophylaxis after kidney transplantation have a more severe outcome when compared to early infections and occur in patients less immunosuppressed early after transplantation.
预防性治疗停止后的晚期巨细胞病毒感染(LCMV)已有充分描述。我们旨在评估一组肾移植患者在未进行巨细胞病毒(CMV)预防性治疗的情况下发生的晚期CMV感染的临床和流行病学数据。
在一组未采用CMV特异性预防性治疗的肾移植受者中,将移植后6个月后发生CMV感染的患者与在最初6个月内诊断为CMV感染的患者(早期感染)进行比较。主要目的是比较临床结局并评估晚期CMV感染的危险因素。
共评估了556例患者。将43例LCMV感染患者与513例早期CMV感染患者进行了比较。LCMV感染发生在移植后中位473天,病程更严重,侵袭性疾病和移植物丢失率在统计学上显著更高(分别为60.5%对21.6%和11.6%对3.1%)。LCMV感染患者的30天死亡率是其两倍,但未达到统计学显著性(9.3%对4.3%)。多因素分析显示,移植后早期使用抗淋巴细胞治疗和将他克莫司作为初始免疫抑制治疗对LCMV感染的发生有显著保护作用。
与早期感染相比,肾移植后在未进行特异性预防性治疗的情况下发生的晚期CMV感染结局更严重,且发生在移植后早期免疫抑制程度较低的患者中。